The many faces of meningococcal disease: A case series and review of presentations and treatment options

Infectious Diseases in Clinical Practice

Volumn 13, Issue 1, 2005, Pages 5-9

  Crum, Nancy F ^a   Chapman, Frank A ^b   Russell, Kevin L ^a   Hale, Braden R ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b Marine Corps Recruit Depot   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATHINE PENICILLIN; CEFTRIAXONE; DEXAMETHASONE; MENINGOCOCCUS VACCINE; PHENYTOIN; PNEUMOCOCCUS VACCINE; VACCINE; VANCOMYCIN;

ADENOVIRUS; ADULT; ANAMNESIS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BACTERIUM CULTURE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; LABORATORY TEST; MALE; MENINGITIS; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; PNEUMONIA; POLYMERASE CHAIN REACTION; REVIEW; SEIZURE; SEPTICEMIA; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; VIRUS INFECTION;

EID: 12144256354     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000152474.47425.5b     Document Type: Review

References (47)

1. Memish ZA. Meningococcal disease and travel. Clin Infect Dis. 2002;34:84-90.
2. Cartwright KA. Early management of meningococcal disease. Infect Dis Clin North AM. 1999;13:661-684.
3. Anonymous. Outbreaks of group B meningococcal disease - Florida, 1995 and 1997. MMWR Morb Mortal Wkly Rep. 1998;47:833-837.
4. Jackson LA, Alexander ER, DeBolt CA, et al. Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease. Pediatr Infect Dis J. 1996;15:992-998.
5. Popovic T, Schmink S, Rosenstein NA, et al. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C. J Clin Microbiol. 2001;39:75-85.
6. Caugant DA, Hoiby EA, Magnus P, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. 1994;32:323-330.
7. Rosenstein NE, Perkins BA, Stephens DA. et al. Meningococcal disease. N Engl J Med. 2001;244:1378-1388.
8. Brundage JF, Zollinger WD. Evolution of meningococcal disease epidemiology in the U.S. Army. In: Vedros NA, eds. Evolution of Meningococcal Disease. Boca Raton, Fla: CRC Press; 1987:5-23.
9. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979-983.
10. Young LS, LaForce FM, Head JJ, et al. A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med. 1972;287:5-9.
11. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA. 1990;264:1271-1275.
12. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991;4:359-395.
13. Outbreak of Group A Streptococcal pneumonia among Marine Corps recruits - California, November 1-December 20, 2002. MMWR Morb Mortal Wkly Rep. February 14, 2003;52:106-109.
14. Vieusseux M. Mé moire sur la maladie qui a regne' a Geveve au printemps de 1805. J Med Chir Pharmacol. 1805;11:163.
15. Weichselbaum A. Ueber die Aetiologie der akuten Meningitis cerebrospinalis. Fortschr d Med Berl. 1887;573:620.
16. Brandtzaeg P, van Deuren M. Current concepts in the role of the host response in Neisseria meningitidis septic shock. Curr Opin Infect Dis. 2002;15:247-252.
17. Bruce M, Rosenstein NE, Capparella J, et al. Meningococcal disease in college students. In: Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, November 18-21, 1999:63.
18. Sumaraju V, Smith LG, Smith SM. Infectious complications in asplenic hosts. Infect Dis Clin North AM. 2001;15:551-565.
19. Merino J, Rodriguez-Valverde V, Lamelas JA, et al. Prevalence of deficits of complement components in patients with recurrent meningococcal infections. J Infect Dis. 1983;148:331.
20. Nadel S, Newport MJ, Booy R, et al. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996;174:878-880.
21. Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet. 1999;353:1049-1053.
22. Emonts M, Hazelzet JA, de Groot R, et al. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis. 2003;3:565-577.
23. Patrick DM, Champagne S, Goh SH, et al. Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis. 2003;37:1183-1188.
24. Yung AP, McDonald MI. Early clinical clues to meningococcaemia. Med J Aust. 2003;178:134-137.
25. Racoosin JA, Whitney CG, Conover C, et al. Serogroup Y, meningococcal disease in Chicago, 1991-1997. JAMA. 1998;280:2094-2098.
26. Koppes GM, Ellenbogen C, Gebhart RJ. Group Y meningococcal disease in United States Air Force recruits. Am J Med. 1977;62:661-666.
27. Salzman MB, Rubin LG. Meningococcemia. Infect Dis Clin North AM. 1996;10:709-725.
28. Bonsell S. Isolated knee joint infection with Neisseria meningitidis. Orthopedics. 2002;25:537-539.
29. Vikram HR, Buencamino RB, Aronin SI. Primary meningococcal arthritis in a prosthetic knee joint. J Infect. 2001;42:279-281.
30. Pollard AJ, Probe G, Trombley C, et al. Evaluation of a diagnostic polymerase chain reaction assay for Neisseria meningitidis in North America and field experience during an outbreak. Arch Pathol Lab Med. 2002;126:1209-1215.
31. Baethgen LF, Moraes C, Weidlich L, et al. Direct-test PCR for detection of meningococcal DNA and its serogroup characterization: standardization and adaptation for use in a public health laboratory. J Med Microbiol. 2003;52:793-799.
32. Oppenheim BA. Antibiotic resistance in Neisseria meningitidis. Clin Infect Dis. 1997;24:S98-S101.
33. Galimand M, Gerbaud G, Guibourdenche M, et al. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl J Med. 1998;339:868-874. Erratum in N Engl J Med. March 11, 1999; 340(10):824.
34. van Deuren M, Brandtzaeg P, van der Meer JWM. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13:144-166.
35. Bachli EB, Vavricka SR, Walter RB, et al. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med. 2003;29:337.
36. de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med. June 2003;31(6):1839- 1847.
37. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345:408-416.
38. White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000;96:3719-3724.
39. Alberio L, Lammle B, Esmon CT. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis. 2001;32:1338-1346.
40. Rivard GE, David M, Farrell C, et al. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. 1995;126:646-652.
41. Powars DR, Rogers ZR, Patch MJ, et al. Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S. N Engl J Med. 1987;317:571-572.
42. de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med. 2003;31:1839-1847.
43. Stiehm ER, Damrosch DS. Factors in the prognosis of meningococcal infection: review of 63 cases with emphasis on recognition and management of the severely ill patient. J Pediatr. 1966;68:457-467.
44. Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North AM. 2001;15:155-169.
45. Harrison L, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286:694-699.
46. Ruggeberg J, Heath PT. Safety and efficacy of meningococcal group C conjugate vaccines. Expert Opin Drug Saf. 2003;2:7-19.
47. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717-722.